<DOC>
	<DOCNO>NCT00002691</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug use drug different way may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat pediatric patient stage III stage IV non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Pediatric Patients With Stage III IV Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I. Assess feasibility treat histologic subgroup pediatric non-Hodgkin 's lymphoma one protocol , addition asparaginase induction consolidation phase diffuse lymphoblastic lymphoma T-cell , large noncleaved cell diffuse lymphoma . II . Assess whether intensification cyclophosphamide induction therapy achieve complete response rate 95 % 1 1.5 month histology . III . Assess whether achieve remission induction 1 month , administer cytarabine/methotrexate continuous infusion consolidation therapy , increase number intrathecal methotrexate injection throughout protocol therapy decrease central nervous system relapse patient . IV . Assess whether 5-year recurrence-free survival 85 % achievable histology protocol . V. Assess whether duration maintenance chemotherapy may stratify stage histology disease avoid unnecessarily prolong chemotherapy . OUTLINE : The follow acronym use : ARA-C Cytarabine , NSC-63878 ASP Asparaginase , NSC-109229 CF Leucovorin , NSC-3590 CTX Cyclophosphamide , NSC-26271 DM Dexamethasone , NSC-34521 DNR Daunorubicin , NSC-82151 G-CSF Granulocyte Colony-Stimulating Factor , NSC-614629 LBL Lymphoblastic Lymphoma LCALKi1B Large Cell Anaplastic B-cell Lymphoma LCALKi1T Large Cell Anaplastic T-cell Lymphoma LCL Large Cell Lymphoma Mesna Mercaptoethane Sulfonate , NSC-113891 MTX Methotrexate , NSC-740 TMP-SMX Trimethoprim-Sulfamethoxazole VCR Vincristine , NSC-67574 VP-16 Etoposide , NSC-141540 Induction : 2-Drug Combination Systemic Chemotherapy plus Single-Agent Intrathecal Chemotherapy follow 2- 3-Drug Combination Systemic Chemotherapy plus Single-Agent Intrathecal Chemotherapy . Part I : CTX/DNR ; plus IT ARA-C ; follow Part II : DM/VCR ; plus ASP patient LBL , T-cell LCL , LCALKi1T ; plus IT MTX . Consolidation : 2- 3-Drug Combination Systemic Chemotherapy Leucovorin Rescue follow 2- 3-Drug Combination Systemic Chemotherapy . Part I : ARA-C/MTX CF ; plus ASP patient LBL , T-cell LCL , LCALKi1T ; follow Part II : ARA-C/VP-16 ; plus , patient LBL , T-cell LCL , LCALKi1T . Maintenance . Single-Agent Systemic Chemotherapy Leucovorin Rescue plus Single-Agent Intrathecal Chemotherapy follow sequentially 3 2-Drug Combination Systemic Chemotherapy Regimens . Part I : MTX ; CF ; plus IT MTX ; follow Part II : CTX/VCR ; follow Part III : ARA-C/VP-16 ; follow Part IV : DNR/DM . PROJECTED ACCRUAL : 25 patients/stratum expect accrued 3 year . This study review early closure 1 patient PD .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : See General Eligibility Criteria PATIENT CHARACTERISTICS : See General Eligibility Criteria</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage III childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
</DOC>